Cargando…

Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()

BACKGROUND: Hypertension (HTN) is the most frequently reported comorbidity in patients with malignancy. This study was conducted to assess the trend of different antihypertensive (AHT) medications used in cancer patients. METHODS: We used the Medical Expenditure Panel Survey (MEPS) database from 200...

Descripción completa

Detalles Bibliográficos
Autores principales: Thyagaturu, Harshith, Alyami, Bandar, Roma, Nicholas, Gonuguntla, Karthik, Bondi, Gayatri, Patel, Brijesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368817/
https://www.ncbi.nlm.nih.gov/pubmed/37502094
http://dx.doi.org/10.1016/j.ijcrp.2023.200196
_version_ 1785077585386930176
author Thyagaturu, Harshith
Alyami, Bandar
Roma, Nicholas
Gonuguntla, Karthik
Bondi, Gayatri
Patel, Brijesh
author_facet Thyagaturu, Harshith
Alyami, Bandar
Roma, Nicholas
Gonuguntla, Karthik
Bondi, Gayatri
Patel, Brijesh
author_sort Thyagaturu, Harshith
collection PubMed
description BACKGROUND: Hypertension (HTN) is the most frequently reported comorbidity in patients with malignancy. This study was conducted to assess the trend of different antihypertensive (AHT) medications used in cancer patients. METHODS: We used the Medical Expenditure Panel Survey (MEPS) database from 2002 to 2019 to identify adult (age >18 years) cancer patients with HTN using appropriate International Classification of Disease (ICD)-9 and ICD-10 codes. Benign and uncertain neoplasms were excluded. P-trend values were calculated using weighted logistic regression with “year” as the predictor variable. RESULTS: We identified ∼46 million adult hypertensive cancer patients with an increasing trend from 2002 to 2019 (3.3 m–6.7 m). Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) use in hypertensive cancer patients increased steadily, while diuretics and combined drugs decreased. Calcium channel blocker (CCB) use increased since 2014–15. In cancer patients with heart failure (HF), beta-blocker (BB) use increased; however, diuretic use peaked in 2014–15 and declined. The use of ACEi/ARB in cancer patients with Diabetes (DM) has increased, whereas BB, CCB, and diuretic use remained stable. Hypertensive cancer patients with Atherosclerotic Cardiovascular Disease (ASCVD) had increased ACEI/ARB use. Combination AHT use has decreased broadly. CONCLUSION: The ACEI/ARB and CCB use trends increased over the past two decades, whereas diuretics have declined. In cancer patients with DM or ASCVD, the use of ACEI/ARB is trending up. BB use showed an increasing trend in patients with HF. Combined AHT and diuretics use decreased. Total expenditure and out-of-pocket expenditure have a decreasing trend for all AHT medications.
format Online
Article
Text
id pubmed-10368817
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103688172023-07-27 Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() Thyagaturu, Harshith Alyami, Bandar Roma, Nicholas Gonuguntla, Karthik Bondi, Gayatri Patel, Brijesh Int J Cardiol Cardiovasc Risk Prev Research Paper BACKGROUND: Hypertension (HTN) is the most frequently reported comorbidity in patients with malignancy. This study was conducted to assess the trend of different antihypertensive (AHT) medications used in cancer patients. METHODS: We used the Medical Expenditure Panel Survey (MEPS) database from 2002 to 2019 to identify adult (age >18 years) cancer patients with HTN using appropriate International Classification of Disease (ICD)-9 and ICD-10 codes. Benign and uncertain neoplasms were excluded. P-trend values were calculated using weighted logistic regression with “year” as the predictor variable. RESULTS: We identified ∼46 million adult hypertensive cancer patients with an increasing trend from 2002 to 2019 (3.3 m–6.7 m). Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) use in hypertensive cancer patients increased steadily, while diuretics and combined drugs decreased. Calcium channel blocker (CCB) use increased since 2014–15. In cancer patients with heart failure (HF), beta-blocker (BB) use increased; however, diuretic use peaked in 2014–15 and declined. The use of ACEi/ARB in cancer patients with Diabetes (DM) has increased, whereas BB, CCB, and diuretic use remained stable. Hypertensive cancer patients with Atherosclerotic Cardiovascular Disease (ASCVD) had increased ACEI/ARB use. Combination AHT use has decreased broadly. CONCLUSION: The ACEI/ARB and CCB use trends increased over the past two decades, whereas diuretics have declined. In cancer patients with DM or ASCVD, the use of ACEI/ARB is trending up. BB use showed an increasing trend in patients with HF. Combined AHT and diuretics use decreased. Total expenditure and out-of-pocket expenditure have a decreasing trend for all AHT medications. Elsevier 2023-07-10 /pmc/articles/PMC10368817/ /pubmed/37502094 http://dx.doi.org/10.1016/j.ijcrp.2023.200196 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Thyagaturu, Harshith
Alyami, Bandar
Roma, Nicholas
Gonuguntla, Karthik
Bondi, Gayatri
Patel, Brijesh
Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
title Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
title_full Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
title_fullStr Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
title_full_unstemmed Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
title_short Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
title_sort trends of antihypertensive use among patients with cancer and hypertension in the united states 2002–2019()
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368817/
https://www.ncbi.nlm.nih.gov/pubmed/37502094
http://dx.doi.org/10.1016/j.ijcrp.2023.200196
work_keys_str_mv AT thyagaturuharshith trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019
AT alyamibandar trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019
AT romanicholas trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019
AT gonuguntlakarthik trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019
AT bondigayatri trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019
AT patelbrijesh trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019